|
gptkbp:instanceOf
|
antidepressant
selective serotonin reuptake inhibitor
|
|
gptkbp:approvedBy
|
1992
|
|
gptkbp:ATCCode
|
N06AB05
|
|
gptkbp:bioavailability
|
50%
|
|
gptkbp:blackBoxWarning
|
increased risk of suicidal thoughts in young people
|
|
gptkbp:brand
|
gptkb:Aropax
gptkb:Paxil
gptkb:Seroxat
|
|
gptkbp:CASNumber
|
61869-08-7
|
|
gptkbp:contraindication
|
concurrent use with MAO inhibitors
hypersensitivity to paroxetine
|
|
gptkbp:developedBy
|
GlaxoSmithKline
|
|
gptkbp:discoveredBy
|
gptkb:Ferrosan
|
|
gptkbp:eliminationHalfLife
|
21 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:genericAvailable
|
yes
|
|
gptkbp:hasMolecularFormula
|
C19H20FNO3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Paroxetine
|
|
gptkbp:KEGGID
|
D02366
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits reuptake of serotonin
|
|
gptkbp:MedlinePlusID
|
a698032
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpired
|
yes
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:pregnancyRisk
|
may cause birth defects
|
|
gptkbp:proteinBinding
|
95%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL418
43815
DB00715
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
weight gain
sweating
insomnia
drowsiness
dry mouth
sexual dysfunction
withdrawal symptoms
|
|
gptkbp:synonym
|
(-)-trans-4R-(4'-fluorophenyl)-3S-[(3',4'-methylenedioxyphenoxy)methyl]piperidine
|
|
gptkbp:UNII
|
0556X3712M
|
|
gptkbp:usedFor
|
gptkb:generalized_anxiety_disorder
gptkb:obsessive-compulsive_disorder
gptkb:panic_disorder
gptkb:post-traumatic_stress_disorder
gptkb:social_anxiety_disorder
gptkb:major_depressive_disorder
premenstrual dysphoric disorder
|
|
gptkbp:bfsParent
|
gptkb:Antidepressants
|
|
gptkbp:bfsLayer
|
6
|